Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Volume: 78, Issue: 12, Pages: 1510 - 1510
Published: Dec 1, 2021
Abstract

Importance

B-cell–depleting therapies may affect the development of a protective immune response following vaccination. Understanding the ability to develop vaccine-specific immunity to COVID-19 in patients with multiple sclerosis (MS) treated with B-cell–depleting therapy is of importance for clinical decisions.

Objective

To assess SARS-CoV-2 vaccine-specific humoral and cellular responses in patients treated with ocrelizumab...
Paper Details
Title
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
Published Date
Dec 1, 2021
Volume
78
Issue
12
Pages
1510 - 1510
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.